Page
PART I FINANCIAL INFORMATION
			Page
PART I - FINANCIAL INFORMATIONItem 1.	Financial Statements (Unaudited)		3
	Condensed Consolidated Balance Sheets		3
	Condensed Consolidated Statements of Operations		4
Item 1.	FinancialCondensed Consolidated Statements (Unaudited)of Comprehensive Loss		45
	Condensed Consolidated Statements of Changes in Stockholders’ Deficit		6
	Unaudited Balance Sheets asCondensed Consolidated Statements of September 30, 2017 and December 31, 2016Cash Flows		47
	Unaudited Statements of Operations for the three and nine months ended September 30, 2017 and 2016		5
	Unaudited Statements of Cash Flows for the nine months ended September 30, 2017 and 2016		6
	Notes to unaudited financial statementsCondensed Consolidated Financial Statements		78
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		1213
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		1415
Item 4.	Controls and Procedures		14
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings		15
PART II - OTHER INFORMATION
Item 2.1.	Unregistered Sales of Equity Securities and Use of ProceedsLegal Proceedings		1518
Item 1A.	Risk Factors		18
Item 3.2.	Defaults Upon SeniorUnregistered Sales of Equity Securities and Use of Proceeds		1518
Item 4.3.	Submission of Matters to a Vote of Security HoldersDefaults Upon Senior Securities		1518
Item 5.4.	Other InformationMine Safety Disclosures		1518
Item 6.5.	ExhibitsOther Information		1618
Item 6.	Exhibits		18

Item 1: Financial Statements.

DLT RESOLUTION, INC   

Condensed Consolidated Balance Sheets

(Unaudited)

Item 1: Financial Statements

HEMCARE HEALTH SERVICES INC.
Balance Sheets
(Unaudited)
		September 30, 2017				December 31, 2016
ASSETS
Intangible assets		$	55,000			$	-
Total assets		$	55,000			$	-
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Bank overdraft		$	7			$	7
Accounts payable and accrued liabilities			106,656				38,772
Dividends payable			25,448				25,448
Related party payables			49,544				39,599
Current notes payables			81,500				332,100
Derivative liability			68,793				-
Convertible notes payable, net of discounts of $0 and $6,916			4,900				23,784
Related party convertible notes payable, net of discounts $0 and $0			-				2,634
Total current liabilities			336,848				462,344
Related party notes payable, net of current portion			10,000				-
Notes payable, net of current portion			85,000				-
Total liabilities			431,848				462,344
Stockholders' deficit
Series A convertible preferred stock, $1.00 par value; 5,000,000 shares authorized, 25,000 and 0 issued and outstanding at September 30, 2017 and December 31, 2016			25,000				-
Common stock, $0.001 par value; 275,000,000 shares authorized; 212,275,211 and 273,332,211 issued; 123,225,211 and 272,952,211 outstanding at September 30, 2017 and December 31, 2016			212,275				273,332
Additional paid in capital			2,902,463				2,613,165
Other comprehensive income			24				24
Treasury stock, 89,050,000 shares			(95,200	)			(100	)
Accumulated deficit			(3,421,410	)			(3,348,765	)
Total stockholders' deficit			(376,848	)			(462,344	)
Total liabilities and stockholders' deficit		$	55,000			$	-

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

DLT RESOLUTION, INC. 

Unaudited Condensed Consolidated Statements of Comprehensive Loss

HEMCARE HEALTH SERVICES INC.
Statements of Operations
(Unaudited)
		Three months ended September 30,								Nine months ended September 30,
		2017				2016				2017				2016
Revenue		$	-			$	-			$	-			$	-
Operating expenses
General and administrative			579				1,162				6,419				8,320
Professional fees			3,121				1,228				14,879				17,116
Total operating expenses			3,700				2,390				21,298				25,436
Other income (expense)
Discharge of indebtedness			-				-				26,306				-
Loss on change in fair market value of derivative liability			(63,886	)			-				(63,445	)			-
Interest expense			(5,218	)			(7,994	)			(14,208	)			(44,525	)
Total other income (expense)			(69,104	)			(7,994	)			(51,347	)			(44,525	)
Net income (loss)		$	(72,804	)		$	(10,384	)		$	(72,645	)		$	(69,961	)
Preferred stock dividends declared			-				(1,591	)			-				(6,448	)
Net income (loss) attributable to common shareholders		$	(72,804	)		$	(11,975	)		$	(72,645	)		$	(76,409	)
Basic and diluted loss per common share		$	(0.00	)		$	(0.00	)		$	(0.00	)		$	(0.00	)
Weighted average shares outstanding - basic			153,917,570				190,258,081				200,403,394				158,118,401

See accompanying notes to unaudited condensed consolidated financial statements.

5

Table of Contents

DLT RESOLUTION, INC

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

HEMCARE HEALTH SERVICES INC.
Statements of Cash Flows
(Unaudited)
		Nine months ended September 30,
		2017				2016
Cash flows from operating activities
Net loss from operations		$	(72,645	)		$	(69,961	)
Adjustments to reconcile net loss to net cash used in operating activities
Forgiveness of debt			(26,306	)			-
Amortization of debt discounts			4,900				28,508
Loss on change in fair market value of derivative liability			63,445				-
Excess fair market value of derivative liability charged to interest			448				-
Expenses paid on behalf of the company by related parties			6,420				-
Changes in operating assets and liabilities
Prepaid expenses			-				2,252
Accounts payable and accrued liabilities			23,738				12,260
Net cash used in operating activities			-				(26,941	)
Net cash used in investing activities			-				-
Cash flows from financing activities
Proceeds from bank overdraft			-				7
Repayments of related party convertible note payable			-				(8,000	)
Proceeds from convertible notes payable			-				17,100
Repayments of convertible note payable			-				(2,500	)
Net cash used in financing activities			-				6,607
Net change in cash			-				(20,334	)
Cash at beginning of period			-				20,334
Cash at end of period		$	-			$	-
Supplemental cash flow information
Cash paid for interest		$	-			$	-
Cash paid for income taxes		$	-			$	-
Non-cash investing and financing activities
Forgiveness of related party convertible note payable		$	2,634			$	-
Forgiveness of related party interest payable		$	606			$	-
Forgiveness of convertible note payable		$	23,783			$	-
Forgiveness of note payable		$	600			$	-
Forgiveness of interest payable		$	1,923			$	-
Common shares issued in exchange for note payable principal		$	250,000			$	-
Account payable entered into for intangible asset		$	55,000			$	-
Accounts payable paid by related party		$	3,425			$	-
Accounts payable paid by convertible noteholder		$	4,900			$	-
Related party note payable entered into for purchase of treasury stock		$	10,000			$	-
Notes payable entered into for purchase of treasury stock		$	85,000			$	-
Related party advance for purchase of treasury stock		$	100			$	-
Preferred dividend declared		$	-			$	6,448
Preferred stock issued for repayment of note payable		$	-			$	18,500
Preferred stock issued for repayment of accrued interest payable		$	-			$	31,500

See accompanying notes to unaudited condensed consolidated financial statements.

6

Table of Contents

DLT RESOLUTION, INC.

HEMCARE HEALTH SERVICES INC.

Notes to Unaudited Condensed Consolidated Financial Statements

SeptemberJune 30, 20172022

Note 1 - Basis– Organization and Significant Accounting Policies

The Company was organized on January 17, 2007 (Date of PresentationInception) under the laws of the State of Nevada, as DBL Senior Care, Inc. and subsequently changed its name to DLT Resolution Inc. on December 4, 2017.

DLT Resolution Inc. (“DLT, the “Company”, “we” and “our”) operates in blockchain applications and telecommunications in Canada and the United States. The Company operates a Health Information Exchange providing the ability to request and retrieve medical information and records while meeting all of today’s security & compliance demands for HIPAA, PIPEDA and PHIPA.

The accompanying unaudited interim financial statements of Hemcare Health Services Inc. (formerly NSU Resources, Inc.) (collectively referred to herein as “Hemcare Health Services”, “Hemcare”, or the “Company”), have been prepared in accordance with accounting principles generally accepted inassuming that the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements for the period ended December 31, 2016 and notes thereto contained in the Company’s Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary forCompany will continue as a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for fiscal 2016 as reported in the form 10-K have been omitted.

Note 2 - Going Concern

going concern. The Company had anhas suffered recurring losses from operations and has a significant accumulated deficit of $3,421,410 and a working capital deficit of $336,848 as of September 30, 2017 and had no revenues.deficit. In addition, the Company continues to experience negative cash flow from operations. These mattersfactors raise substantial doubt about the Company’sCompany's ability to continue as a going concern. ContinuationThe financial statements do not include any adjustments that might result from the outcome of the Company’s existence depends upon its ability to obtain additional capital.this uncertainty. Management’s plans in regards to this matter include raising additional equity financing and borrowing funds under a private credit facility and/or other credit sources. These

Interim Condensed Consolidated Financial Statements

The accompanying unaudited condensed consolidated financial statements dohave been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and in conformity with the instructions to Form 10-Q and Article 8 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. However, we believe that the disclosures included in these condensed consolidated financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements included in this document have been prepared on the same basis as the annual consolidated financial statements, and in our opinion reflect all adjustments, which include normal recurring adjustments necessary for a fair presentation in accordance with US GAAP and SEC regulations for interim financial statements. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that we will have for any adjustments that might result fromsubsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the outcome of this uncertainty.audited consolidated financial statements and the notes to those statements for the year ended December 31, 2021 included in our Annual Report on Form 10-K as filed with the SEC on March 13, 2023.

Note 3 - Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities disclosuresand disclosure of contingent assets and liabilities as ofat the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from thesethose estimates.

Cash Equivalents

Income taxes

The Company considers all highly liquid investments with maturities of three months or less atIncome taxes are provided for using the time of purchase to be cash equivalents.

Prior Period Conformity

The Company has reclassified balances in the prior period financial statements for conformity with the current period for comparison purposes.

Income Taxes

The Company accounts for income taxes under the asset and liability method whereof accounting in accordance with FASB ASC Topic 740 (formally SFAS No. 109 “Accounting for Income Taxes”). A deferred tax assetsasset or liability is recorded for all temporary differences between financial and liabilitiestax reporting. Temporary differences are recognized for the future tax consequences attributable to differences between the financial statements carryingreported amounts of existing assets and liabilities and their respective tax bases.basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enactedadjusted for the effect of changes in tax laws and rates expected to apply to taxable income inon the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.date of enactment.

At SeptemberJune 30, 2017,2022, there were no uncertain tax positions that require accrual.

7

Table of Contents

Revenue Recognition

HEMCARE HEALTH SERVICES INC.

NotesThe Company follows ASC 606 of the FASB Accounting Standards Codification for revenue recognition. The Company recognizes revenue upon the transfer of promised services to Unaudited Financial Statements

September 30, 2017customers in amounts that reflect the consideration to which the Company expects to be entitled the transfer of services. The Company considers revenue earned when all the following criteria are met: (i) the contract with the customer has been identified, (ii) the performance obligations have been identified, (iii) the transaction price has been determined, (iv) the transaction price has been allocated to the performance obligations, and (v) the performance obligations have been satisfied. The Company primarily generates revenues through the sale of products through its website and at industry tradeshows.

Note 3 - Significant Accounting Policies (continued)

Intangible Asset

During the nine months ended September 30, 2017, the Company entered into an agreement whereby a third party would build a web portal as part of executing our business plan. Through September 30, 2017, we had incurred $55,000 of costs to build the portal which are included in accounts payable as of September 30. The portal has yet to be launched and as such there has been no amortization recorded or impairment as of September 30, 2017.

Net Income (Loss) Per Share

Net loss per share is calculated in accordance with FASB ASC topic 260. Basic lossearnings (loss) per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. period, assuming conversion or exercise of all potentially dilutive securities outstanding during each reporting period presented. Potentially dilutive securities are not presented or used in the computation of diluted loss per share on the statement of operations for periods when the Company incurs net losses, as their effect would be anti-dilutive.

As of SeptemberJune 30, 2017, there was a2022 and December 31, 2021, the Company had 64,000 shares of Series B Convertible Preferred Stock issued and outstanding, which were convertible note outstanding that could convert to a total of 490,000 common shares. Becauseinto 12,800 shares of the net loss incurredCompany’s Common Stock.

Foreign Currency Translation

The functional currency of the Company’s subsidiaries in Canada is the Canadian Dollar. The subsidiaries’ assets and liabilities have been translated to U.S. dollars using exchange rates of 0.776940 and 0.782656 in effect at the balance sheet dates of June 30, 2022 and December 31, 2021, respectively. Unaudited condensed consolidated statements of operations amounts have been translated using the weighted average exchange rates of 0.780382 for the six months ended June 30, 2022 and 0.814408 for the six months ended June 30, 2021. Resulting gains or losses from translating foreign currency financial statements are recorded as other comprehensive income (loss). Foreign currency transaction gains and losses resulting from exchange rate fluctuations on transactions denominated in a currency other than the local currency are included in other income (expense). Foreign currency transaction gains (losses) recognized for the six-month periods ended June 30, 2022 and 2021 were $14 and ($55), respectively.

Fair value of certain of the Company’s financial instruments including cash, prepaid expenses, accounts payable, accrued expenses, notes payable, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value investments.

Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of non-performance, which includes, among other things, the Company’s credit risk.

Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values.

Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the three and nine months ended September 30, 2017,period attributable to the impacts of dilutive instruments would have been anti-dilutivefollowing: (i) total gains or losses for the period presented(realized and have been excluded from loss per share calculations. There were no potentially dilutive instruments outstanding at September 30, 2016.unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of income.

Derivative LiabilitiesNote 2 – Discontinued Operations

The Company recordssuspended the operations of Union Strategies, Inc. in 2022and recognizes its activities as discontinued operations within the accompanying unaudited condensed consolidated financial statements.  All assets are written off and included in the loss from discontinued operations. In 2023, the Company sold its 100% ownership of USI to a debt discount relatedthird party for a nominal payment and the acquirer assumed all of USI’s liabilities on a nonrecourse basis.  In connection with the sale, the Company received 2,000,000 shares of its Common Stock held by an individual who sold USI shares to the issuance of convertible debts that have conversion features at adjustable rates. The debt discount for the convertible instruments is recognized and measured by allocating a portion of the proceeds as an increaseCompany in additional paid-in capital and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion features. The debt discount will be accreted by recording additional non-cash gains and losses related to the change in fair market values of derivative liabilities over the life of the convertible notes.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

Note 4 - Related Party Transactions

No salaries were paid to directors or executives during the periods ended September 30, 2017 or 2016.January 2020.

On January 31, 2017,March 15, 2023, the Company entered intosold its 100% ownership of DLT Data Services Inc. to a mutual release agreement withthird party for a related party with which there was an outstanding convertible note of $2,634nominal purchase price and outstanding accrued interest of $1,923. The agreement forgavehas recognized its activities as discontinued operations within the outstanding payables and they were written to $0 against additional paid in capital on the date of the agreement.accompanying unaudited condensed consolidated financial statements.

Note 3 – Intangible Assets

During the nine months ended SeptemberWe amortize identifiable intangible assets on a straight-line basis over their estimated useful lives. As of June 30, 2017, a related party paid $6,419 of expenses, $3,426 of outstanding payables on behalf of the company and $100 to repurchase treasury stock on behalf of the Company. The advances are due on demand and are included in current liabilities as a result. There was $49,544 and $39,599 due to related parties as of September 30, 20172022 and December 31, 2016.2021, identifiable intangibles were as follows:

Note 4 – Notes Payable

On August 1, 2017, the Company entered intoissued a $10,000non-interest bearing $5,000 note payable with a related party to purchase 3,000,000 common shares as treasury stock. The note requires payments of $5,000due on July 1, 2019 $2,500 on July 1, 2020 and $2,500 plus all accrued interest on July 31,to a third party in exchange for Company Common Stock held by the third party. As of June 30, 2022, and accrues interest at 3% per annum. There was $10,000 of principal and accrued interest of $49 due as of September 30, 2017.the note is unpaid.

8

Table of Contents

HEMCARE HEALTH SERVICES INC.

Notes to Unaudited Financial Statements

September 30, 2017

Note 5 – Stockholders’ Equity

Series A Convertible Preferred StockCommon stock

During the three months ended June 30, 2022, the Company sold 388,274 shares of restricted Common stock to third parties and received $184,577 in proceeds.

Common stock subscribed

The Company is authorizedsold a subscription to issue up to 5,000,000purchase 14,000 shares of Series A Convertible Preferred Stock. The Series A Convertible Preferredits Common Stock can be convertedfor $14,000 on April 24, 2020. To date, the shares have not been issued to common shares at the optionpurchaser.

Note 6 – Related Party Transactions

No compensation was incurred for the services of the holder at a rate equal to $0.10 per share.Company’s directors or executives during the periods ended June 30, 2022 and 2021.

During the nine months ended SeptemberAs of June 30, 2017, the Company issued 25,000 shares of Series A Convertible Preferred Stock in exchange for 2,417,000 shares of common stock.

There were 25,000 and 0 shares of series A convertible preferred stock issued and outstanding as of September 30, 20172022 and December 31, 2016. Additionally,2021, the Company had accrued dividendsoutstanding amounts payable to related parties of $59,729 and $60,017. The obligations are unsecured, non-interest bearing, due on series A convertible preferred stock totaling $25,448 at September 30, 2017demand and payable in Canadian dollars, with the change in the liability from December 31, 2016.